Acute coronary syndrome
Drug research and approvals for acute coronary syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 210 studies of acute coronary syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, and the EU has 9 authorised medicines for it.
- Recruiting worldwide: 210
- Trials authorized in Canada: 11
- FDA orphan approvals: 0
- EU medicines: 9
- Implementing the 6th Generation Cardiac Troponin TNCT07936630 · Not applicable · Rasmus Bo Hasselbalch · starts Aug 1, 2026
- Real-World Outcomes of Drug-Coated Balloon Angioplasty in Coronary Artery DiseaseNCT07875088 · Not reported · Kristian Rivera · starts Oct 16, 2026
- Aspirin 50mg vs 100mg Combined With P2Y12 Inhibitor After PCINCT07846462 · Not applicable · Jilin University · starts Mar 1, 2026
- Analysis of Life-threatening ARrhythMias After Acute Coronary SyndromeNCT07824050 · Not reported · Catharina Ziekenhuis Eindhoven · starts Jul 14, 2026
- Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary SyndromeNCT07824323 · Phase 4 · Taipei Medical University Hospital · starts Aug 26, 2026
- Smartphone AI Assistance for Prehospital ECG InterpretationNCT07810686 · Not applicable · École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital Care · starts Sep 2, 2026
- TwichView-guided Atricurium Dose Adjustment TrialNCT07807046 · Not applicable · Fu Jen Catholic University Hospital · starts Aug 19, 2026
- A Single-Center, Retrospective, Propensity-Score-Matched Cohort Study Comparing Drug-Coated Balloon Versus Drug-Eluting…NCT07806370 · Not reported · Xijing Hospital · starts Jan 1, 2019
- Fatigue Investigation Using Digital OutcomesNCT07783074 · Not reported · Liliana Barrios · starts May 26, 2026
Approved 7
- TicagrelorPurinergic receptor P2Y12 negative allosteric modulator
- ClopidogrelPurinergic receptor P2Y12 antagonist
- PrasugrelPurinergic receptor P2Y12 antagonist
- RivaroxabanCoagulation factor X inhibitor
- BivalirudinThrombin inhibitor
- EptifibatideIntegrin alpha-IIb/beta-3 inhibitor
- CangrelorPurinergic receptor P2Y12 antagonist
Phase 3 12 of 24
- AspirinCyclooxygenase inhibitor
- AtorvastatinHMG-CoA reductase inhibitor
- HeparinAntithrombin-III activator
- LosmapimodMAP kinase p38 alpha inhibitor
- ApixabanCoagulation factor X inhibitor
- RosuvastatinHMG-CoA reductase inhibitor
- EvolocumabSubtilisin/kexin type 9 inhibitor
- TirofibanIntegrin alpha-IIb/beta-3 inhibitor
- DalcetrapibCholesteryl ester transfer protein inhibitor
- Varespladib methylPhospholipase A2 group IIA inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- FondaparinuxAntithrombin-III activator
Phase 2 12 of 15
- ColchicineTubulin inhibitor
- BisoprololBeta-1 adrenergic receptor antagonist
- AtopaxarProteinase-activated receptor 1 antagonist
- AliskirenRenin inhibitor
- ValsartanType-1 angiotensin II receptor antagonist
- RanolazineSodium channel protein type V alpha subunit blocker
- PentoxifyllineAdenosine A2 receptor antagonist
- PegnivacoginCoagulation factor IX inhibitor
- LetaxabanCoagulation factor X inhibitor
- AtreleutonArachidonate 5-lipoxygenase inhibitor
- DarexabanCoagulation factor X inhibitor
- Iodofiltic acid
Phase 1 or earlier 10
- Enoxaparin sodiumAntithrombin-III activator
- TemanogrelSerotonin 2a (5-HT2a) receptor inverse agonist
- Sumecigrel
- CitalopramSerotonin transporter inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- MoxifloxacinTopoisomerase IV inhibitor
- VorapaxarProteinase-activated receptor 1 antagonist
- PantoprazolePotassium-transporting ATPase inhibitor
- Thiosulfuric acid
- BMS-919373
How its trials ended
1,335 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 303 whose ending is known, 47% met their primary endpoint, 17% missed it and 36% stopped early.
- Completed, result not reported51238%
- Status unknown29222%
- Ongoing22817%
- Met its primary endpoint14311%
- Missed its primary endpoint504%
- Stopped: other or unclear484%
- Stopped: enrollment or feasibility353%
- Stopped: sponsor or business decision161%
- Stopped: lack of efficacy71%
- Stopped: funding3<1%
- Stopped: safety1<1%
| Sep 12, 2025 | A randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of early in hospital initiation of inclisiran treatment in patients with…Inclisiran (KJX839) | Novartis Pharmaceuticals | Ongoing |
| Apr 25, 2023 | A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined…Dalcetrapib (RO4607381) | Dalcor Pharmaceuticals Canada Inc. | Ongoing |
| Apr 12, 2023 | A phase 3, randomized, double-blind, placebo-controlled, event-driven study to demonstrate the efficacy and safety of milvexian, an oral factor xia inhibitor,…Milvexian (JNJ-70033093, BMS-986177) | Johnson & Johnson | Closed |
| Sep 15, 2021 | Open-label, sequential-dose escalation/de-escalation trial testing MT1002 in patients undergoing pci due to acute coronary syndrome with nstemiMT1002 | Shaanxi Micot Technology Co. Ltd | Ongoing |
| Sep 30, 2016 | Multiple-dose, dose-finding placebo controlled double-blind randomized trial to compare the effect of treatment on plaque burden determined by ivus; evaluate…MDCO-216 | Medicines | Pending |
| Jan 20, 2016 | A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined…Dalcetrapib | Dalcor Pharma Ukltd, Swiss Branch | Ongoing |
| Aug 27, 2015 | A phase Ib study of duvalumab (MEDI-4736) with or without tremelimumab in patients with advanced incurable solid malignancies receiving standard chemotherapy…MEDI4736 / Tremelimumab / Abraxane / Carboplatin | Ncic Clinical Trials Group Queens University | Ongoing |
| Aug 26, 2015 | A placebo-controlled, double-blind, randomized trial to compare the effect of treatment on plaque burden as determined by ivus and to evaluate the efficacy,…MDCO-216 (dimeric rapoa-im/popc),… | Medicines | Ongoing |
| May 29, 2015 | An open-label, 2 x 2 factorial, randomized controlled, clinical trial to evaluate the safety of apixaban vs. vitamin k antagonist and aspirin vs. aspirin…Eliquis (apixaban; BMS-562247)/ Acetylsalicylic acid | Bristol-Myers Squibb | Closed |
| May 6, 2015 | A randomized, double-blind, double-dummy, active-controlled, parallel-group, multicenter study to compare the safety of rivaroxaban versus acetylsalicylic acid…Xarelto (rivaroxaban, bay 59-7939)/ Aspirin (acetylsalicylic acid) | Johnson & Johnson | Closed |
| Nov 16, 2020 | Rivaroxaban AccordRivaroxaban · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Jan 9, 2020 | Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan)Clopidogrel; acetylsalicylic acid · generic | Mylan Pharmaceuticals Limited | EMA ↗ |
| May 15, 2018 | Prasugrel Viatris (previously Prasugrel Mylan)Prasugrel · generic | Viatris Limited | EMA ↗ |
| Mar 23, 2015 | KengrexalCangrelor | Chiesi Farmaceutici S.p.A. | EMA ↗ |
| Mar 14, 2010 | DuoPlavinClopidogrel; acetylsalicylic acid | Sanofi Winthrop Industrie | EMA ↗ |
| Mar 14, 2010 | Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)Clopidogrel; acetylsalicylic acid | Sanofi-Aventis Groupe | EMA ↗ |
| Jul 27, 2009 | Clopidogrel Teva (hydrogen sulphate)Clopidogrel · generic | Teva Pharma B.V. | EMA ↗ |
| Feb 24, 2009 | EfientPrasugrel | Substipharm | EMA ↗ |
| Sep 30, 2008 | XareltoRivaroxaban | Bayer AG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA